A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The study has the purpose to evaluate in elderly and/or cardiopathic HL patients, the
cardiologic toxicity of the MBVD regimen, where liposomal doxorubicin (Myocet®) is
substituted for doxorubicin in the conventional ABVD regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione Italiana Linfomi ONLUS
Collaborator:
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte